Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
Portfolio Pulse from
Rigel Pharmaceuticals announced initial data from its Phase 1b study of R289 in LR-MDS patients, showing promising results with 40% response in certain patients. The drug was well tolerated, indicating potential for further development.
December 09, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals shared promising initial data from its Phase 1b study of R289, showing a 40% response rate in certain LR-MDS patients and good tolerance, potentially boosting investor confidence.
The announcement of positive initial data from a clinical study can lead to increased investor confidence and potential stock price appreciation. The 40% response rate and good tolerance are significant for a Phase 1b study, indicating potential for further development and success in later trials.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100